latest news releases from the newsroom
Investing Advice for JDS Uniphase, DELL, EMC and Qwest from StockPickReport
SHREVEPORT, La., May 23, 2005 (PRIMEZONE) -- StockPickReport.Com (IARD No. 119079, http://www.stockpickreport.com -- the web's only non-mainstream stock rating service), rates JDS Uniphase, Dell Inc, EMC Corporation, Qwest Communications International Inc.
TelePlus Enterprises, Inc.
TelePlus' MVNO Division Signs Two U.S. Licensing Agreements, Deal Expected to Increase Revenues by $4M
MONTREAL, May 23, 2005 (PRIMEZONE) -- TelePlus Enterprises, Inc. (OTCBB: TLPE) (http://www.teleplus.ca), a vertically integrated provider of wireless and landline communications products and services across North America, is pleased to announce today its subsidiary, TelePlus Wireless Corp. ("TelePlus Wireless"), operating the Company's Mobile Virtual Network ("MVNO"), signed licensing agreements (the "Agreements") with E-Mobile group of Companies, LLC ("E-Mobile") from Dallas, Texas and Skynet PCS ("Skynet"), from Milwaukee, Wisconsin.
Industrial Nanotech, Inc.
Industrial Nanotech Launches Nansulate Translucent Product Line
NAPLES, Fla., May 23, 2005 (PRIMEZONE) -- Industrial Nanotech Inc., (Pink Sheets:INTK), an emerging nanotechnology-based solutions provider, announces the introduction of the Nansulate(tm) Translucent product line consisting of the Nansulate GP and Nansulate PT. Nansulate(tm) Translucent is an industrial grade coating which provides both insulation and anti-corrosion protection and is designed for higher performance applications commonly seen in industries such as the maritime, petroleum refinery and shipbuilding industries among others.
BioXell Enters License Agreement with Merck & Co., Inc. for TREM-1 Product Candidate and TREM Platform
MILAN, Italy, May 23, 2005 (PRIMEZONE) -- BioXell SpA, the Italian biopharmaceutical company, today announced that it has signed an exclusive, worldwide license agreement with Merck & Co., Inc. for development of TREM related therapeutic and diagnostic products. Under the agreement, Merck obtains exclusive rights to develop BioXell's initial product candidate directed to TREM-1 currently in preclinical development, and other candidates directed to the TREM-1 target. Merck and BioXell will also collaborate on the further research of other TREM receptors.